Today: 9 June 2026
Legal & General share price: LGEN ticks up as L&G names new real assets chiefs, Banner Life sale in focus
28 January 2026
2 mins read

Legal & General share price: LGEN ticks up as L&G names new real assets chiefs, Banner Life sale in focus

London, Jan 28, 2026, 09:43 GMT — Regular session

  • Legal & General shares gained roughly 0.8% in early London trading
  • L&G appointed Tim Morris and Philipp Westermann as global co-heads of Real Assets within its asset management division
  • Investors also took in new details on the planned sale of Banner Life and William Penn to Japan’s Meiji Yasuda

Legal & General shares climbed 0.8% to 262.8 pence on Wednesday, pushing the rally into a second day. The FTSE 100 insurer remains roughly 2.4% shy of its early-January highs. The stock started at 261.6 pence and hit an intraday peak of 264.7 pence, per LSE data.

The move arrives as investors seek proof that Legal & General can sustain fee income growth while streamlining the group and maintaining strict control over capital — all with a significant U.S. disposal still pending regulatory approval.

As January comes to a close, scrutiny has intensified. Traders juggle corporate updates alongside changing rate forecasts—a volatile combo for life insurers, whose balance sheets depend heavily on bond markets.

London shares held steady in early trading Wednesday, following Tuesday’s 0.6% rise powered by gains in bank stocks. Attention turned to the U.S. Federal Reserve’s policy announcement later in the day, seen as a key factor for global bond yields.

Legal & General on Wednesday appointed Tim Morris and Philipp Westermann, co-managing partners at Proprium Capital Partners, as global co-heads of Real Assets in its asset management division. Eric Adler, L&G’s asset management CEO, described the hires as “a signal of how well our organisations are working together.” Group CEO António Simões emphasized that faster growth in real assets is “central” to the company’s private markets strategy. group.legalandgeneral.com

Legal & General and Meiji Yasuda Life confirmed yesterday they still aim to close the sale of Banner Life and its New York unit William Penn in early 2026, pending final regulatory sign-offs. The firms reported writing about $1.8 billion in premium across 15 U.S. pension risk transfer (PRT) deals this year. In these arrangements, insurers take on pension payouts from corporate plans in exchange for an upfront premium.

L&G announced a shake-up in its legal leadership. Geoffrey Timms, the long-time general counsel and company secretary, will step down following the group’s May AGM. His deputy, Maria Alvarez-Scott, is set to take the helm. Simões described Timms as “central” to the company’s growth. group.legalandgeneral.com

The company released new figures from its Home Finance division, revealing that half of new lifetime mortgage customers in 2025 tapped housing equity for home improvements. Meanwhile, fewer borrowers used the product to pay off mortgage debt. Lorna Shah, managing director for retail retirement at L&G, said “property wealth can play an important role” in boosting retirement income. group.legalandgeneral.com

Some remain uneasy about the current situation. UBS weighed in this week, favoring Aviva over Legal & General. The reason? L&G’s greater vulnerability to market shocks and a likely “medium-term solvency ratio drag.” The solvency ratio, a key regulatory capital metric, is under close scrutiny by insurance investors. Interactive Investor

Bond markets are still in focus. The UK 10-year gilt yield hovered near 4.5% late Tuesday. Insurers often react to yield shifts since these impact investment returns and the valuation of their long-term liabilities.

The biggest risk: a delay in the U.S. sale timetable. Should regulators drag their feet, investors could grow skeptical about how fast the balance sheet is shrinking and how much capital can be returned. This concern grows sharper if central-bank moves unsettle the wider markets.

Legal & General will release preliminary full-year results on March 11. Investors will focus on capital levels, timing of asset disposals, and the impact of the private markets strategy on earnings.

Stock Market Today

  • JNK India Shares Surge 13% After UAE Order Win, Stock Nears Double in 2026
    June 9, 2026, 9:14 AM EDT. JNK India shares jumped 13% on June 9 following a major order win from UAE's CC7 Emirates Engineering Solutions, enhancing revenue visibility. The contract for waste gas handling systems includes design, manufacturing, and commissioning for ADNOC's TA'ZIZ Salt Project, due by December 2027. This large order, valued between ₹100 crore and ₹5,000 crore, boosted investor confidence amid robust industrial demand. The stock has surged nearly 96% year-to-date, outperforming the broader market. Trading volumes rose sharply, reflecting strong investor interest. JNK India's strong order pipeline underpins its growth outlook in the energy and process industries.

Latest articles

AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

Grab Stock Barely Moves As Taiwan Push And Singapore Merchant Plan Put Growth Back In Focus

9 June 2026
Grab shares hovered near $3.33 in pre-market trading after unveiling a new Singapore merchant programme and Taiwan partner commitments, as investors weigh growth initiatives against regulatory hurdles and consumer spending pressure; the stock’s muted move reflects ongoing uncertainty around its proposed foodpanda Taiwan acquisition and potential margin impacts from promotions.
Carvana stock rises after Wells Fargo target hike, but options traders lean defensive
Previous Story

Carvana stock rises after Wells Fargo target hike, but options traders lean defensive

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom
Next Story

Dow Jones flattens near 49,000 as S&P 500 hits 7,000; Fed and Big Tech earnings loom

Go toTop